TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A USC Schaeffer Center model estimates that donanemab could generate $104,900 in lifetime societal value per person when used at the timing studied in a clinical trial. Starting treatment two years earlier raised that estimate by 32%, to $138,300, but the calculations exclude drug, screening and monitoring costs and depend on how long treatment effects last.
Starting the Alzheimer’s drug donanemab two years earlier could raise its estimated lifetime societal value by 32%, according to modeling by researchers at the USC Schaeffer Center for Health Policy & Economics. The study, published Oct. 7 in Alzheimer’s & Dementia, projects gains for patients, care partners and public programs, but does not subtract the costs of the drug or the screening and monitoring needed to provide it.
The researchers used a dynamic microsimulation model to estimate lifetime outcomes for a group resembling participants in a pivotal Phase 3 trial. They compared three scenarios: treatment at the timing used in the trial, treatment beginning two years earlier while still after symptoms typically emerge, and no treatment. These are model projections, not a trial directly comparing those treatment start dates.
For the trial-timing scenario, the model estimated that donanemab, marketed as Kisunla, would add about 0.3 years of life and reduce time spent with severe dementia by one year compared with no treatment. It also projected 0.37 additional disability-free years and 0.63 more years living in the community. Researchers valued the combined lifetime benefits at $104,900 per person.
About half of that estimate, or $52,300, came from improved health-related quality of life. The model attributed another $23,800 to reduced unpaid caregiving and $22,200 to medical-cost offsets, largely accruing to Medicaid. It estimated annual Medicaid savings of about $1,640 per person, or 13%. When treatment began two years earlier, the projected value rose to $138,300, a 32% increase over the trial-timing estimate.
Earlier Diagnosis Could Change Treatment Value
The findings connect the timing of diagnosis to the potential returns from treatment. The researchers say Alzheimer’s is diagnosed, on average, 3.5 years after symptoms begin, leaving a gap between the onset of symptoms and a formal diagnosis. If a treatment works better earlier in the disease course, reducing that delay could increase the time patients spend living independently and reduce some care needs.
The modeled value extends beyond a patient’s health. It includes estimates of quality of life, unpaid care and medical-cost offsets, linking treatment timing to families and public budgets as well as patients. That perspective may inform discussion about access and the resources needed to identify eligible people. However, the estimates are not a calculation of net savings: drug and delivery costs were excluded, so the study does not establish whether earlier treatment would save money overall or be cost-effective under particular coverage arrangements.
The authors also examined hypothetical future medicines. A treatment that slowed progression by 50% was assigned an estimated lifetime social value of $208,700 to $276,700, depending on start time; a treatment that halted progression was modeled at $530,000 to $648,300. Those figures describe scenarios, not currently available treatments or demonstrated clinical results.
Products Worth Considering
Levoit Core 400S-P Smart Air Purifier for Large Rooms
iRobot Roomba Max 715 Pet Robot Vacuum with AutoEmpty Dock
Samsung 48-Inch S90H OLED 4K Smart TV (2026)
As an affiliate, we earn on qualifying purchases.
Diagnosis Delays and the Model
The study addresses a policy question raised by new Alzheimer’s medicines and diagnostic tools: how might long-term benefits change if treatment starts earlier? The source report says several blood-based biomarker tests received FDA approval in the prior year and that digital cognitive assessments could also help identify people at earlier stages. It does not establish that these tools alone can resolve delays or that every person identified would be eligible for treatment.
For its donanemab estimates, the team drew on national health surveys and studies of dementia progression, using a commonly used cognitive-status measure to project outcomes over a lifetime. For both treatment scenarios, the model applied a 29% slowing of disease progression, matching the drug’s result versus placebo after 18 months in the trial. The model was developed through the Schaeffer Center’s U.S. Cost of Dementia Project, described as a federally funded effort to quantify dementia’s total costs.
The researchers tested a more favorable scenario in which donanemab had a stronger slowing effect, drawing on emerging evidence. Under that assumption, the model’s value estimate rose to $179,400 for the trial-timing group, 71% above its main estimate. They also tested a conservative case in which the treatment effect lasted four years rather than the patient’s remaining lifetime. In that case, estimated value fell by half to $49,100, while starting two years earlier still raised it by 15%, to $56,400.
“Our research suggests that investments in early detection could help ensure that patients start treatments when they’re more likely to provide the greatest benefit to patients and society.”
— Jack Chapel, lead author, USC Schaeffer scholar and assistant research professor at the USC Price School of Public Policy
Costs and Treatment Duration Remain Open
The study’s estimates depend on assumptions about how much donanemab slows progression and how long that effect lasts. The researchers say the treatments are new and that the duration of their benefits remains uncertain. Their four-year-effect scenario produced substantially lower lifetime values than the main model, illustrating how sensitive projections are to that question.
The analysis also leaves out the costs of the drug, screening and monitoring. It therefore cannot show the net financial impact of earlier treatment, how costs would be shared among patients, insurers and public programs, or whether expanded screening would be worthwhile in a given health system. The reported societal-value figures are model outputs rather than amounts paid or savings already recorded.
The report does not provide enough detail to determine how the estimates would apply to patients unlike the trial-like group, or how practical barriers such as coverage restrictions and the process of identifying and monitoring eligible patients would affect real-world access. Those questions require evidence beyond this model.
Evidence Needed for Broader Access Decisions
The findings may inform future decisions about diagnosis, treatment access and health-system spending, but they do not prescribe a screening policy or establish that every patient should start treatment earlier. Further evidence on how long treatment benefits persist, how well trial results translate to routine care, and the full costs of treatment and delivery will help test the projections.
The research also points to a wider pipeline: the source report says more than 150 Alzheimer’s drugs were undergoing clinical testing. Those candidates would need to demonstrate their effects in studies before estimates for hypothetical treatments could be treated as evidence about available care. For now, the central finding is a modeled one: earlier donanemab treatment raised estimated lifetime value, while the net benefit in practice remains unresolved.
Key Questions
What did the study estimate about earlier donanemab treatment?
The model estimated a lifetime societal value of $138,300 per person when treatment began two years earlier than in the trial-timing scenario, compared with $104,900 at trial timing. The higher figure is a projection, not an observed result from a trial comparing those start dates.
What does “societal value” include in this analysis?
The estimate combines modeled health-related quality-of-life gains, reductions in unpaid caregiving and medical-cost offsets. It is not the same as a cash saving, and it excludes the costs of the drug, screening and monitoring.
Does the study show that earlier treatment saves money?
No. The model projected some medical-cost offsets, including Medicaid savings, but excluded treatment and delivery costs. It does not establish the net financial effect of earlier treatment.
How certain are the projected benefits?
The estimates depend on assumptions about how much the drug slows disease progression and how long its effects last. In a scenario where the effect lasted four years rather than the patient’s lifetime, the modeled value was cut in half, though the earlier-start scenario remained higher.
Source: rss
